An open-label, multi-centre, extension study evaluation the long-term safety and tolerability of Degarelix one-month depots in patients with prostate cancer

• Conditions: Prostate Cancer; MedDRA version: 7.0Level: pr tClassification code 10060862

• Registration Number: EUCTR2004-003814-40-HU
• Lead Sponsor: Ferring Pharmaceuticals A/S

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2004-11-09
• Last Update Posted: 19 March 2012

Recruitment & Eligibility

• Status: ot Recruiting
• Sex: Not specified
• Target Recruitment: 130

Inclusion Criteria

•Has given written consent prior to any study-related activity is performed. A study-related activity is defined as any procedure that would not have been performed during the normal management of the patient.
•Has completed the FE200486 CS12 study

Are the trial subjects under 18? no
Number of subjects for this age range:
F.1.2 Adults (18-64 years) yes
F.1.2.1 Number of subjects for this age range
F.1.3 Elderly (>=65 years) yes
F.1.3.1 Number of subjects for this age range

Exclusion Criteria

Has been withdrawn from the FE200486 CS12 study

Study & Design

• Study Type: Interventional clinical trial of medicinal product
• Study Design: Not specified